Free Trial

UnitedHealth Group (UNH) Stock Forecast & Price Target

UnitedHealth Group logo
$540.87 +17.67 (+3.38%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$532.54 -8.32 (-1.54%)
As of 06:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
21

Based on 21 Wall Street analysts who have issued ratings for UnitedHealth Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 21 analysts, 19 have given a buy rating, and 2 have given a strong buy rating for UNH.

Consensus Price Target

$629.32
16.35% Upside
According to the 21 analysts' twelve-month price targets for UnitedHealth Group, the average price target is $629.32. The highest price target for UNH is $700.00, while the lowest price target for UNH is $559.00. The average price target represents a forecasted upside of 16.35% from the current price of $540.87.
Get the Latest News and Ratings for UNH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for UnitedHealth Group and its competitors.

Sign Up

UNH Analyst Ratings Over Time

TypeCurrent Forecast
4/4/24 to 4/4/25
1 Month Ago
3/5/24 to 3/5/25
3 Months Ago
1/5/24 to 1/4/25
1 Year Ago
4/5/23 to 4/4/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
19 Buy rating(s)
19 Buy rating(s)
17 Buy rating(s)
14 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$629.32$629.32$628.37$578.38
Forecasted Upside16.35% Upside32.15% Upside22.49% Upside27.01% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Remove Ads

UNH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

UNH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

UnitedHealth Group Stock vs. The Competition

TypeUnitedHealth GroupMedical CompaniesS&P 500
Consensus Rating Score
3.10
2.82
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside16.35% Upside19,371.98% Upside25.02% Upside
News Sentiment Rating
Positive News

See Recent UNH News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/28/2025Wells Fargo & Company
3 of 5 stars
Stephen Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$694.00 ➝ $660.00+21.46%
1/17/2025Barclays
3 of 5 stars
Andrew Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$655.00 ➝ $642.00+24.45%
1/17/2025KeyCorp
3 of 5 stars
M. Gillmor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$650.00 ➝ $650.00+25.39%
1/17/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sarah James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$700.00 ➝ $700.00+36.71%
1/10/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
1/10/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$595.00+11.26%
1/6/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$625.00 ➝ $610.00+18.91%
1/2/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$605.00 ➝ $600.00+18.61%
12/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$610.00 ➝ $640.00+14.74%
12/5/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$605.00 ➝ $675.00+10.54%
12/3/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$595.00 ➝ $625.00+2.72%
10/18/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$601.00 ➝ $609.00+7.84%
10/16/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$680.00 ➝ $650.00+13.16%
10/16/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$615.00 ➝ $595.00+7.31%
10/16/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$675.00 ➝ $650.00+17.23%
10/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$615.00 ➝ $610.00+10.02%
7/17/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$570.00 ➝ $600.00+4.95%
7/17/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$597.00 ➝ $640.00+16.60%
7/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$481.00 ➝ $647.00+17.88%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$546.00 ➝ $559.00+15.75%
3/13/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
7/18/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$595.00 ➝ $603.00+24.55%
7/11/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$600.00 ➝ $549.00+18.56%
6/14/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$625.00 ➝ $560.00+13.98%
4/17/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$590.00 ➝ $600.00+17.24%
4/14/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingStrong-Buy$630.00+24.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:31 AM ET.


Should I Buy UnitedHealth Group Stock? UNH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 30, 2025. Please send any questions or comments about these UnitedHealth Group pros and cons to contact@marketbeat.com.

UnitedHealth Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in UnitedHealth Group:

  • UnitedHealth Group has a strong market capitalization of $471.51 billion, indicating its significant presence and stability in the healthcare sector.
  • The current stock price is $515.47, which reflects a solid performance and potential for growth, especially considering its 1-year high of $630.73.
  • Institutional investors own 87.86% of the stock, suggesting strong confidence from major financial entities in the company's future prospects.
  • The company has demonstrated resilience with a price-to-earnings ratio of 33.26, which, while high, indicates that investors are willing to pay a premium for its earnings potential.
  • Recent insider activity shows that Director Timothy Patrick Flynn increased his stake in the company, which can be a positive signal about the company's future performance.

UnitedHealth Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in UnitedHealth Group for these reasons:

  • The company has a debt-to-equity ratio of 0.74, which, while manageable, indicates that it has a significant amount of debt compared to its equity, potentially posing risks in economic downturns.
  • UnitedHealth Group's stock has experienced volatility, with a 1-year low of $436.38, suggesting that there may be fluctuations that could impact short-term investors.
  • The current ratio of 0.83 indicates that the company may have liquidity issues, as it has less current assets than current liabilities, which could affect its ability to meet short-term obligations.
  • With a beta of 0.62, the stock is less volatile than the market, which may not appeal to investors looking for high-risk, high-reward opportunities.
  • Recent selling by Arrowstreet Capital Limited Partnership, which cut its holdings by 25.7%, may raise concerns about the company's future performance among other investors.

UNH Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for UnitedHealth Group is $629.32, with a high forecast of $700.00 and a low forecast of $559.00.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UnitedHealth Group in the last year. There are currently 19 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UNH shares.

According to analysts, UnitedHealth Group's stock has a predicted upside of 16.35% based on their 12-month stock forecasts.

Over the previous 90 days, UnitedHealth Group's stock had 2 upgrades by analysts.

UnitedHealth Group has been rated by research analysts at Barclays, Cantor Fitzgerald, Hsbc Global Res, HSBC, KeyCorp, Truist Financial, and Wells Fargo & Company in the past 90 days.

Analysts like UnitedHealth Group more than other "medical" companies. The consensus rating for UnitedHealth Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how UNH compares to other companies.


This page (NYSE:UNH) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners